Construction of a DNA vaccine encoding Flk-1 extracellular domain and C3d fusion gene and investigation of its suppressing effect on tumor growth

Cancer Immunology, Immunotherapy

Volumn 59, Issue 1, 2010, Pages 93-101

  Liang, Pei He ^a   Zhang, Ke Qin ^a   Xu, Gui Lian ^b   Li, Yan Feng ^a   Wang, Luo Fu ^a   Nie, Zhi Lin ^a   Ye, Jin ^a   Wu, Gang ^a   Ge, Cheng Guo ^a   Jin, Feng Shuo ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adjuvant; C3d; DNA vaccine; Flk 1; Tumor

Indexed keywords

CANCER VACCINE; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT COMPONENT C3D VASCULOTROPIN RECEPTOR 2 FUSION PROTEIN; DNA VACCINE; HYBRID PROTEIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC GENE THERAPY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLADDER CARCINOMA; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL STRAIN COS7; CONTROLLED STUDY; EUKARYOTIC CELL; FEMALE; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSFECTION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RECOMBINANT PLASMID; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TUMOR VASCULARIZATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COMPLEMENT C3D; FEMALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; URINARY BLADDER NEOPLASMS; VACCINES, DNA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 70350096110     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0727-2     Document Type: Article

References (25)

1. J Folkman 1971 Tumor angiogenesis: therapeutic implication N Engl J Med 285 1182 1186 4938153 1:STN:280:DyaE38%2FgvVCqsQ%3D%3D
2. TA Bhat RP Singh 2008 Tumor angiogenesis-A potential target in cancer chemoprevention Food Chem Toxicol 46 1334 1345 10.1016/j.fct.2007.08.032 17919802 1:CAS:528:DC%2BD1cXitlOitrw%3D (Pubitemid 351258200)
3. A Bamias MA Dimopoulos 2003 Angiogenesis in human cancer: implications in cancer therapy Eur J Intern Med 14 459 469 10.1016/j.ejim.2003.10.003 14962697 1:CAS:528:DC%2BD2cXhtV2rsb4%3D (Pubitemid 38210170)
4. GE Koehl F Wagner O Stoeltzing, et al. 2007 Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability Transplantation 83 607 614 10.1097/01.tp.0000253756.69243.65 17353782 1:CAS:528:DC%2BD2sXislaitL0%3D (Pubitemid 46440251)
5. AG Niethammer R Xiang JC Becker, et al. 2002 A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth Nat Med 8 1369 1375 10.1038/nm794 12415261 1:CAS:528:DC%2BD38XptVSgsbo%3D (Pubitemid 36019421)
6. FH Rad H Le Buanec S Paturance, et al. 2007 VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases Proc Natl Acad Sci USA 104 2837 2842 10.1073/pnas.0611022104 17301234 1:CAS:528: DC%2BD2sXisVSntrc%3D (Pubitemid 46327966)
7. RA Reisfeld AG Niethammer Y Luo, et al. 2004 DNA vaccines designed to inhibit tumor growth by suppression of angiogenesis Int Arch Allergy Immunol 133 295 304 10.1159/000077009 14988601 1:CAS:528:DC%2BD2cXivVKiu7k%3D (Pubitemid 38529223)
8. JY Liu YQ Wei L Yang, et al. 2003 Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2 Blood 102 1815 1823 10.1182/blood-2002-12-3772 12750177 1:CAS:528:DC%2BD3sXntFaqsrw%3D (Pubitemid 37022578)
9. T Boehm J Folkman T Browder, et al. 1997 Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390 404 407 10.1038/37126 9389480 1:CAS:528:DyaK2sXns12rsL8%3D (Pubitemid 28027321)
10. N Ferrara 2002 VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 795 803 10.1038/nrc909 12360282 1:CAS:528:DC%2BD38XnsVGrtbk%3D (Pubitemid 37328914)
11. JM Hou JY Liu L Yang, et al. 2005 Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities Oncology 69 81 87 10.1159/000087303 16088235 1:CAS:528:DC%2BD2MXoslKgt70%3D (Pubitemid 41207061)
12. P Alessi C Ebbinghaus D Neri 2004 Molecular targeting of angiogenesis Biochim Biophys Acta 1654 39 49 14984766 1:CAS:528:DC%2BD2cXhsVKhsbw%3D
13. A Abdollahi KE Lipson X Han, et al. 2003 SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro Cancer Res 63 3755 3763 12839971 1:CAS:528:DC%2BD3sXltVGqsrk%3D
14. S Singhal A Vachani D Antin-Ozerkis, et al. 2005 Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review Clin Cancer Res 11 3974 3986 10.1158/1078-0432.CCR-04-2661 15930332 1:CAS:528:DC%2BD2MXks1Glu7c%3D (Pubitemid 40791561)
15. PW Dempsey ME Allison S Akkaraju, et al. 1996 C3d of complement as a molecular adjuvant: bridging innate and acquired immunity Science 271 348 350 10.1126/science.271.5247.348 8553069 1:CAS:528:DyaK28XlsFarsQ%3D%3D
16. L Wang JO Sunyer LJ Bello 2004 Fusion to C3d enhances the immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus J Virol 78 1616 1622 10.1128/JVI.78.4.1616-1622.2004 14747527 1:CAS:528:DC%2BD2cXhtFKgtbk%3D (Pubitemid 38176694)
17. H Fan T Tong H Chen, et al. 2007 Immunization of DNA vaccine encoding C3d-VP1 fusion enhanced protective immune response against foot-and-mouth disease virus Virus Genes 35 347 357 10.1007/s11262-007-0105-0 17497212 1:CAS:528:DC%2BD2sXnvFeisr0%3D (Pubitemid 47087559)
18. TD Green BR Newton PA Rota, et al. 2001 C3d enhancement of neutralizing antibodies to measles hemagglutinin Vaccine 20 242 248 10.1016/S0264-410X(01) 00266-3 11567770 1:CAS:528:DC%2BD3MXmvVyhtbc%3D (Pubitemid 32905337)
19. JP Hannan KA Young JM Guthridge, et al. 2005 Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d J Mol Biol 346 3 845 858 10.1016/j.jmb.2004.12.007 15713467 1:CAS:528:DC%2BD2MXhsVCiur8%3D (Pubitemid 40247722)
20. MW Hess MG Schwendinger EL Eskelinen, et al. 2000 Tracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2 (CR2, CD21) Blood 95 2617 2623 10753842 1:CAS:528:DC%2BD3cXisVaitrc%3D
21. A Cherukuri PC Cheng SK Pierce 2001 The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens J Immunol 167 163 167 11418645 1:CAS:528:DC%2BD3MXkslSqtbs%3D
22. Y Konozo R Abe H Konozo, et al. 1998 Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cell J Immunol 160 1565 1572
23. JF Bower TM Ross 2006 A minimum CR2 binding domain of C3d enhances immunity following vaccination Adv Exp Med Biol 586 249 264 10.1007/0-387-34134- X-17 16893077 1:CAS:528:DC%2BD1MXhtFWitLw%3D
24. JF Jegou P Chan MT Schouft, et al. 2007 C3d binding to the myelin oligodendrocyte glycoprotein results in an exacerbated experimental autoimmune encephalomyelitis J Immunol 178 3323 3331 17312184 1:CAS:528: DC%2BD2sXhvFSiu70%3D (Pubitemid 46333218)
25. PM Knopf DS Rivera SH Hai, et al. 2008 Novel function of complement C3d as an autologous helper T-cell target Immunol Cell Biol 86 221 225 10.1038/sj.icb.7100147 18180801 1:CAS:528:DC%2BD1cXjsFChtLw%3D